node_id	target	category	weight	source
AO1	cancer	AO	0.08961748633879782	RE10
AO1	cancer	AO	0.4108352144469526	RE14
AO1	cancer	AO	0.4763157894736842	RE16
AO2	adipogenesis	AO	0.1502659574468085	RE33
AO3	hepatic steatosis	AO	0.2888631090487239	RE37
AO4	steatosis	AO	0.9501160092807425	RE37
AO2	adipogenesis	AO	0.9676855895196507	RE46
AO1	cancer	AO	0.10765002290426019	RE103
AO1	cancer	AO	0.10765002290426019	RE104
KE277	decrease thyroid hormone synthesis	KE	-0.75	RE4
KE342	increased lethality	KE	8.5	RE4
KE1030	increased 	KE	1.0	RE4
KE808	decreased testosterone	KE	1.5	RE7
KE210	oxidative stress	KE	1.0	RE6
KE249	production reactive oxygen species	KE	-0.75	RE6
KE257	increase reactive oxygen species production	KE	-1.0	RE6
KE1030	increased 	KE	1.0	RE6
KE1115	increased reactive oxygen species	KE	1.25	RE6
KE1249	oxidative stress 	KE	1.0	RE6
KE1392	oxidative stress 	KE	1.0	RE6
KE1445	increase lipid peroxidation	KE	2.3333333333333335	RE6
KE756	hippocampal gene expression altered 	KE	-1.25	RE5
KE881	increased triglyceride	KE	2.0	RE5
KE1030	increased 	KE	1.0	RE5
KE1239	altered gene expression	KE	1.6666666666666667	RE5
KE1447	obesity	KE	1.0	RE5
KE1454	chronic high fat diet	KE	-0.75	RE5
KE1030	increased 	KE	1.0	RE8
KE315	decreased body length	KE	1.6666666666666667	RE3
KE330	decrease fertility	KE	2.0	RE3
KE417	skewed sex ratio	KE	1.0	RE3
KE864	decreased body weight	KE	1.6666666666666667	RE3
KE1030	increased 	KE	1.0	RE3
KE1262	apoptosis	KE	1.0	RE9
KE1030	increased 	KE	1.0	RE10
KE1447	obesity	KE	1.0	RE10
KE1030	increased 	KE	1.0	RE13
KE220	increase plasma vitellogenin concentrations	KE	-1.25	RE11
KE577	impaired development	KE	1.0	RE11
KE808	decreased testosterone	KE	1.0	RE11
KE1030	increased 	KE	1.0	RE11
KE1015	increased neuronal synaptic inhibition	KE	-4.0	RE12
KE1030	increased 	KE	1.0	RE12
KE122	activation glucocorticoid receptor	KE	2.0	RE15
KE494	glucocorticoid receptor agonist activation	KE	-1.5	RE15
KE742	decreased androgen receptor activity	KE	-1.25	RE15
KE785	activation androgen receptor	KE	1.6666666666666667	RE15
KE1030	increased 	KE	1.0	RE15
KE1396	increased glucocorticoid receptor activity	KE	-1.5	RE15
KE1030	increased 	KE	1.0	RE17
KE210	oxidative stress	KE	1.0	RE19
KE1238	activation oxidative stress pathway	KE	-2.25	RE19
KE1249	oxidative stress 	KE	1.0	RE19
KE1262	apoptosis	KE	1.0	RE19
KE1392	oxidative stress 	KE	1.0	RE19
KE1030	increased 	KE	1.0	RE22
KE1065	activation estrogen receptor alpha	KE	-1.0	RE23
KE1030	increased 	KE	1.0	RE27
KE249	production reactive oxygen species	KE	-0.75	RE32
KE1115	increased reactive oxygen species	KE	-0.75	RE32
KE1030	increased 	KE	1.0	RE33
KE1030	increased 	KE	1.0	RE38
KE1030	increased 	KE	1.0	RE37
KE1447	obesity	KE	1.0	RE37
KE130	depletion gsh	KE	1.0	RE39
KE249	production reactive oxygen species	KE	-0.75	RE39
KE1030	increased 	KE	1.0	RE39
KE1115	increased reactive oxygen species	KE	-0.75	RE39
KE1278	ros formation	KE	1.0	RE39
KE1445	increase lipid peroxidation	KE	1.0	RE39
KE119	gap	KE	1.0	RE40
KE1030	increased 	KE	1.0	RE40
KE1030	increased 	KE	1.0	RE45
KE1030	increased 	KE	1.0	RE44
KE167	activation lxr	KE	3.0	RE46
KE344	liver fibrosis	KE	5.5	RE46
KE756	hippocampal gene expression altered 	KE	-0.75	RE46
KE1060	alteration lipid metabolism	KE	2.6666666666666665	RE46
KE1157	activation hepatic nuclear receptor(s)	KE	-2.0	RE46
KE1239	altered gene expression	KE	1.0	RE46
KE1421	activated lxr	KE	3.0	RE46
KE1263	necrosis	KE	1.0	RE2
KE210	oxidative stress	KE	1.0	RE53
KE1249	oxidative stress 	KE	1.0	RE53
KE1392	oxidative stress 	KE	1.0	RE53
KE1030	increased 	KE	1.0	RE54
KE1030	increased 	KE	1.0	RE57
KE446	reduction testosterone level	KE	2.3333333333333335	RE59
KE1030	increased 	KE	1.0	RE59
KE1030	increased 	KE	1.0	RE61
KE1194	increase dna damage	KE	1.0	RE61
KE1281	increased dna damage repair	KE	-0.75	RE61
KE1030	increased 	KE	1.0	RE64
KE1030	increased 	KE	1.0	RE69
KE1030	increased 	KE	1.0	RE70
KE1030	increased 	KE	1.0	RE73
KE1447	obesity	KE	1.0	RE73
KE1030	increased 	KE	1.0	RE76
KE1030	increased 	KE	1.0	RE79
KE294	unknown	KE	1.0	RE81
KE1030	increased 	KE	1.0	RE81
KE1113	unknown 	KE	1.0	RE81
KE1030	increased 	KE	1.0	RE82
KE1262	apoptosis	KE	1.0	RE82
KE1030	increased 	KE	1.0	RE84
KE1447	obesity	KE	1.0	RE84
KE1065	activation estrogen receptor alpha	KE	-1.0	RE86
KE1030	increased 	KE	1.0	RE89
KE210	oxidative stress	KE	1.0	RE90
KE1249	oxidative stress 	KE	1.0	RE90
KE1278	ros formation	KE	2.0	RE90
KE1392	oxidative stress 	KE	1.0	RE90
KE1030	increased 	KE	1.0	RE97
KE312	allergic contact dermatitis challenge	KE	-0.75	RE101
KE1193	breast cancer	KE	1.0	RE103
KE1193	breast cancer	KE	1.0	RE104
KE201	binding antagonist nmda receptors	KE	-1.5	RE110
KE1065	activation estrogen receptor alpha	KE	-3.0	RE110
KE1180	estrogen receptor activation 	KE	4.0	RE110
KE1181	activation estrogen receptor	KE	4.0	RE110
KE1447	obesity	KE	1.0	RE110
